New Alzheimer's drug shows promise in early trial
Disease control
Completed
This study tested an experimental drug called 50561 in 68 people with mild to moderate Alzheimer's disease. The goal was to see if it could slow down memory and thinking decline compared to a placebo. The trial was double-blind, meaning neither patients nor doctors knew who got t…
Phase: PHASE2 • Sponsor: Beijing Joekai Biotechnology LLC • Aim: Disease control
Last updated May 04, 2026 16:23 UTC